中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于北京诺思兰德生物技术股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 中国·北京 BEIJING CHINA . . . . China Audit Asia Pacific Certified Public Accountants LLP. 关于北京诺思兰德生物技术股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 中审亚太审字(2025)003477 号 北京诺思兰德生物技术股份有限公司全体股东: 我们接受委托,对后附的北京诺思兰德生物技术股份有限公司(以下简称"诺 思兰德") 截至 2024 年 12 月 31 日止的《2024 年度募集资金存放与实际使用情 况的专项报告》进行了鉴证工作。 按照北京证券交易所颁布的《北京证券交易所股票上市规则(试行)》《北 京证券交易所上市公司持续监管指引第 9 号一募集资金管理》等相关规定,编制 《2024 年度募集资金存放和实际使用情况的专项报告》,提供真实、合法、完整 的实物证据、原始书面材料、副 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-026 北京诺思兰德生物技术股份有限公司 2024 年度独立董事述职报告（徐辉） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为北京诺思兰德生物技术股份有限公司（以下简称"公司"）的独立 董事，2024 年度，本人严格按照《公司法》、《证券法》、《上市公司独立董 事管理办法》及《北京证券交易所上市公司持续监管指引第 1 号——独立董事》 等有关法律、法规及《独立董事工作制度》和《公司章程》的相关规定和要求， 认真履行独立董事职责，及时了解公司的经营状况，按时出席公司召开的相关会 议并认真审议各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事 的作用，切实维护了公司和全体股东特别是中小股东的合法权益。现将本人 2024 年履职情况报告如下： 一、个人基本情况 本人现就职于北京兴华会计师事务所（特殊普通合伙），任合伙人。2020 年 6 月至今，任公司独立董事，兼任公司董事会审计委员会委员、董事会薪酬与 考核委员会委员。 20 ...

Financial Performance - The company's operating revenue for 2024 reached ¥72,110,862.43, representing a year-over-year increase of 20.84% compared to ¥59,675,141.95 in 2023[31]. - The gross profit margin improved to 54.40% in 2024, up from 49.20% in 2023[31]. - The net loss attributable to shareholders decreased to ¥45,180,740.62 in 2024 from ¥48,134,821.42 in 2023[31]. - Total assets increased by 45.54% to ¥477,534,006.34 at the end of 2024, compared to ¥328,120,719.02 at the end of 2023[33]. - Total liabilities decreased by 26.07% to ¥97,217,059.37 at the end of 2024, down from ¥131,496,996.06 at the end of 2023[33]. - The net assets attributable to shareholders surged by 116.33% to ¥331,442,284.06 at the end of 2024, compared to ¥153,212,884.84 at the end of 2023[33]. - The company reported a basic earnings per share of -0.17 in 2024, an improvement from -0.19 in 2023[31]. - The cash flow from operating activities showed a net outflow of ¥39,782,131.84 in 2024, compared to an outflow of ¥37,613,636.33 in 2023[33]. - The company received government subsidies amounting to ¥10,479,843.04 in 2024, which is an increase from ¥8,778,416.79 in 2023[38]. - Non-recurring gains and losses totaled ¥13,449,893.54 in 2024, compared to ¥9,359,988.38 in 2023[39]. Share Issuance and Capital Structure - In January 2024, the company issued 16,106,071 shares of common stock at a price of RMB 14.33 per share, raising a total of RMB 230,799,997.43[8]. - The company has a total of 274,271,974 shares of common stock outstanding[23]. - The company’s total number of shares decreased to 274,271,974 after the cancellation of stock options and restricted shares[142]. - The company repurchased and canceled 602,000 shares of restricted stock at a price of RMB 4.30 per share, totaling RMB 2,588,600[145]. - The company raised a total of CNY 247,583,028.98 through public offerings, with a net amount of CNY 229,007,628.31 after deducting issuance costs[166]. - The company has a remaining balance of 124,395,588.51 RMB from the raised funds as of December 31, 2024[162]. - The company plans to use the raised funds for drug research and development, biological engineering new drug projects, and to replenish working capital[162]. Research and Development - The company has 11 biopharmaceutical projects in the pipeline, including 5 gene therapy drugs and 6 recombinant protein drugs, with the core project NL003 having completed Phase III clinical trials and submitted a drug registration application for ulcer indications[42]. - The company has established core technology platforms for gene therapy, recombinant proteins, and ophthalmic drugs, enhancing its R&D capabilities[51]. - R&D expenditure for the current period is CNY 43,566,589.92, representing 60.42% of operating revenue, a decrease from 72.88% in the previous period[98]. - The company has 64 R&D personnel, accounting for 35.56% of total employees, an increase from 57 personnel in the previous period[101]. - The company is in the early evaluation stage for a gene therapy product aimed at treating osteoarthritis, indicating a commitment to innovative treatment options[104]. - The company is developing multiple new products, including RD3001 for dry eye syndrome and RD3002 for ptosis, both of which are in the research phase[104]. - The company has not capitalized any R&D expenditures, maintaining a 0% capitalization rate[98]. Market and Product Development - The company is focused on expanding its market presence with innovative products aimed at addressing unmet medical needs[104]. - The company is in the process of launching several new eye care products, including RD3003, RD3004, and RD4001, which are expected to enhance competitiveness and profitability[105]. - The company is developing a new product, RD4005, for the treatment of dry eye disease, with significant market potential as there are currently no similar products available domestically[106]. - The company is also working on RD4006, aimed at alleviating symptoms of dry eyes and visual fatigue, which will further diversify its product line[106]. - The company is in the national review stage for several products, including RD4001 and RD4002, which are expected to have a broad market outlook[105]. Regulatory and Compliance - The company received a registration acceptance notice for NL003 from the National Medical Products Administration in July 2024, marking a step towards domestic production approval[9]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its annual report[14]. - The company has established a comprehensive quality management system and drug vigilance system to ensure drug quality throughout its lifecycle[117]. - The company is committed to establishing a compliance management system to strengthen business compliance oversight and improve overall operational efficiency[126]. - The company has received a clean audit report from Zhongshui Yatai Accounting Firm, confirming its financial integrity and compliance with regulations[113]. Strategic Initiatives - A new subsidiary was established in Shanghai in August 2024, aimed at enhancing the company's strategic planning and commercialization efforts[9]. - The company is focusing on the commercialization of NL003, including building a sales operation system and expanding the sales team to increase market share[125]. - The company is actively optimizing its management processes and has passed inspections for drug production license additions, enhancing its operational compliance and risk management[47]. - The company is committed to expanding its market share by actively exploring target markets and ensuring drug efficacy meets clinical needs[124]. Industry Context - The pharmaceutical manufacturing industry is expected to maintain stable growth, driven by an aging population and increasing chronic disease management needs, with over 210 million people aged 65 and above in China[121]. - The national medical insurance drug list now includes 3,159 drugs, significantly boosting the innovation drive within the pharmaceutical industry[194]. - The cumulative savings from centralized drug procurement since 2018 have reached approximately 161.4 billion yuan, demonstrating substantial cost efficiency[194]. - The government work report emphasizes the promotion of innovative drugs, marking a significant policy shift in the healthcare sector[193]. Risks and Challenges - The company acknowledges uncertainties in macro policies affecting drug registration, pricing, and market access, which could impact its operational strategies[128]. - The company faces risks related to the lengthy and complex drug development process, which may lead to delays in project timelines and potential failures in achieving development goals[129]. - The company is actively seeking to expand its ophthalmic drug pipeline and enhance sales and CDMO service market promotion to mitigate ongoing losses[130].

Financial Performance - Net profit attributable to shareholders was CNY -7,716,806.44, an improvement from CNY -12,250,307.09 in the same period last year[10] - Operating revenue increased by 1.85% to CNY 16,420,451.13 compared to CNY 16,121,526.48 in the previous year[10] - The company's basic earnings per share improved to CNY -0.03 from CNY -0.05 in the previous year[10] - The weighted average return on net assets based on net profit attributable to shareholders was -2.36%, an improvement from -4.13% in the same period last year[10] - Net loss for Q1 2025 was ¥6,783,601.29, an improvement compared to a net loss of ¥11,280,541.80 in Q1 2024[34] - Comprehensive loss for Q1 2025 totaled ¥7,043,386.09, compared to a comprehensive loss of ¥11,521,154.71 in Q1 2024[34] - Total comprehensive income for Q1 2025 was -8,742,195.99, an improvement from -13,593,141.73 in Q1 2024, showing a reduction in comprehensive losses by about 35.5%[38] Assets and Liabilities - Total assets decreased by 8.63% to CNY 436,312,529.93 compared to the end of the previous year[10] - The company's asset-liability ratio decreased to 14.45% from 20.36% year-on-year[10] - Total current assets amounted to CNY 174,502,470.71 as of March 31, 2025, compared to CNY 237,983,211.85 on December 31, 2024, reflecting a decrease of approximately 26.7%[27] - Non-current assets totaled CNY 261,810,059.22 as of March 31, 2025, up from CNY 239,550,794.49 on December 31, 2024, indicating an increase of about 9.3%[28] - Total liabilities decreased from CNY 97,217,059.37 on December 31, 2024, to CNY 63,038,969.05 as of March 31, 2025, a reduction of about 35.2%[29] - The company's equity attributable to shareholders decreased from CNY 331,442,284.06 on December 31, 2024, to CNY 323,465,692.82 as of March 31, 2025, a decline of approximately 2.9%[29] Cash Flow - Cash flow from operating activities was CNY -18,923,393.62, a significant decline from CNY -5,456,755.62 in the same period last year[10] - Cash flow from operating activities for Q1 2025 was -18,923,393.62, worsening from -5,456,755.62 in Q1 2024[39] - Cash flow from investment activities for Q1 2025 was -78,630,405.71, compared to -158,861,228.05 in Q1 2024, indicating a decrease in cash outflow by approximately 50.5%[40] - The cash inflow from financing activities amounted to $224.20 million, with a net cash flow of $214.11 million after outflows[43] - The net increase in cash and cash equivalents was -$38.77 million, contrasting with an increase of $50.06 million in the prior period[43] Shareholder Information - The total number of ordinary shares outstanding at the end of the reporting period was 274,271,974, with 65.67% held by the controlling shareholder[16] - The top ten shareholders collectively held 127,690,083 shares, representing 46.56% of total shares, with no shareholder pledging or freezing their shares[18][20] - The number of ordinary shareholders was 7,446 at the end of the reporting period[17] Research and Development - Research and development expenses decreased by 45.17% to CNY 6,627,675.84 due to reduced expenses related to ongoing projects[13] - Research and development expenses for Q1 2025 were ¥6,627,675.84, a decrease from ¥12,088,644.58 in Q1 2024, indicating a potential shift in investment strategy[33] - Research and development expenses for Q1 2025 were 5,593,288.44, down from 11,464,739.20 in Q1 2024, a reduction of about 51.1%[37] Government Support and Other Income - The company received government subsidies amounting to CNY 135,089.18, related to personal income tax refund projects[14] - Non-recurring gains and losses totaled CNY 359,433.64, with a net amount of CNY 288,011.76 after tax impacts and minority interests[14] - The company reported a fair value change gain of CNY 235,139.66 from financial assets and liabilities[14] Compliance and Governance - The company has not disclosed any major litigation or arbitration matters during the reporting period[23] - There were no significant related party transactions or fund misappropriation incidents reported[23] - The company has complied with all internal review procedures for significant events and disclosed them in a timely manner[23] - The company has not undergone any accounting policy changes or error corrections during the reporting period[15]

一、主要会计数据和财务指标 前十大流通股东累计持有： 3599.54万股，累计占流通股比： 19.99%，较上期变化： -228.85万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 许成日 | 1553.20 | 8.62 | 不变 | | 李相哲 | 714.44 | 3.97 | -71.37 | | 中国银行股份有限公司-富国积极成长一年定期开放混合 型证券投资基金 | 358.81 | 1.99 | 不变 | | 安文娟 | 350.33 | 1.95 | 0.69 | | 海南爱科时代科技有限公司 | 347.00 | 1.93 | 新进 | | 沈超英 | 275.76 | 1.53 | -86.47 | | 较上个报告期退出前十大股东有 | | | | | 魏巍 | 418.70 | 2.32 | 退出 | 三、分红送配方案情况 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | - ...

Group 1 - The report highlights that as of Q1 2025, the market value of public funds heavily invested in the Beijing Stock Exchange (BSE) reached 6.743 billion, a quarter-on-quarter increase of 24.5% [3][4] - The allocation scale and ratio of public funds continue to grow, driven by the spring technology theme, with a notable increase in the importance of stock selection [3][8] - The active equity public funds have shown increased attention towards BSE stocks, with the allocation coefficient reaching 0.43, up by 0.05 from the previous quarter [3][9] Group 2 - The report indicates that the BSE 50 index fund experienced slight redemptions, but future inflows are still anticipated, with the total scale reaching 9.258 billion, an increase of 1.479 billion [3][16] - The average net value growth rate of thematic funds in 2025 is 39.1%, outperforming the BSE 50 index's growth of 30.6% [3][19] - The report emphasizes a focus on active equity public funds, with new additions to the top ten heavy stocks including Kaitai Co., Minsida, and Norsland, further concentrating on Jinbo Biological [3][20] Group 3 - The report notes that active public funds are increasing their holdings in consumer sectors and companies with strong earnings reports, with six of the top ten stocks showing a profit growth rate exceeding 20% in 2024 [3][24] - The report identifies a shift towards consumer sectors, with an emphasis on "consumption + technology" as highlighted in the 2025 Two Sessions, leading to increased allocations in companies like Jinbo Biological and Kangnong Seed [3][26] - The report also mentions a decrease in heavy allocations in sectors such as electric equipment, machinery, and automobiles, while increasing in beauty care, light manufacturing, and agriculture [3][26]

证券代码：430047 证券简称：诺思兰德 公告编号：2025-029 北京诺思兰德生物技术股份有限公司 会计师事务所履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 北京诺思兰生物技术股份有限公司（以下简称"公司"）聘请中审亚太会计师事 务所（特殊普通合伙）（以下简称"中审亚太会计师事务所"）作为公司 2024 年年度 审计机构。根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会 颁布的《国有企业、上市公司选聘会计师事务所管理办法》，公司对中审亚太会计师事 务所在近一年审计中的履职情况进行了评估。经评估，公司认为中审亚太会计师事务 所资质等方面合规有效，履职保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、2024 年度审计机构的基本情况 （一）基本情况 会计师事务所名称：中审亚太会计师事务所（特殊普通合伙） 2024 年度末签署过证券服务业务审计报告的注册会计师人数：180 人 2024 年收入总额（经审计）：70397.66 万元 成立日期：2013 年 1 月 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-032 北京诺思兰德生物技术股份有限公司 关于 2025 年度董事、监事、高级管理人员薪酬方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京诺思兰德生物技术股份有限公司（以下简称"公司"）根据相关法律法 规、《公司章程》及公司《董事会薪酬与考核委员会工作细则》等相关制度的规 定，结合公司实际经营情况，参考所处行业的薪酬水平，拟定了 2025 年度董事、 监事及高级管理人员薪酬方案。现将方案具体内容公告如下： 一、2025 年度董事、监事及高级管理人员薪酬方案 （一）、适用对象 公司董事、监事及高级管理人员 （二）、适用期限 2025 年 1 月 1 日-2025 年 12 月 31 日 （三）、薪酬标准 （2）未在公司担任其他职务的监事，职务津贴为 10 万元/年（税前）。 3、公司高级管理人员薪酬方案： 公司高级管理人员根据其在公司担任的具体管理职务，按公司相关薪酬标 准与绩效考核办法领取薪酬。 二、审议程序 2025 年 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-023 北京诺思兰德生物技术股份有限公司 2024 年度内部控制评价报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带法律责任。 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管 要求（以下简称企业内部控制规范体系），结合北京诺思兰德生物技术股份有限 公司（以下简称"公司或本公司"）内部控制制度和评价办法，在内部控制日 常监督和专项监督的基础上，我们对截止 2024 年 12 月 31 日（以下简称：基准 日）公司的内部控制有效性进行了评价。 部控制。 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基 准日，公司未发现非财务报告内部控制重大缺陷。 自内部控制评价报告基准日至内部控制评价报告发出日之间，未发生影响 内部控制有效性评价结论的因素。 三、内部控制评价工作情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高 风险领域。纳入评价范围的主要单位包括：公司及子公司北京诺思兰 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-031 北京诺思兰德生物技术股份有限公司 2024 年度募集资金存放与实际使用情况的专项报告 注 1：杭州银行北京分行（账号 1101040160001268555）于 2024 年 6 月注销，详见 2024-055 号《关于注销部分募集资金专项账户的公告》。 注2：杭州银行北京分行（账号 1101040160001278083）于 2023 年 11 月注销，详见2023-097 号《关于注销部分募集资金专项账户的公告》。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 公司自精选层挂牌以来共进行两次股票发行，截至 2024 年 12 月 31 日，两 次股票发行基本情况如下: （一）向不特定合格投资者公开发行 公司于 2020 年 9 月 30 日收到中国证券监督管理委员会下发的《关于核准北 京诺思兰德生物技术股份有限公司向不特定合格投资者公开发行股票的批复》 （证监许可〔2020〕2473 号），核准本公司向不 ...